Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Adjuvant Treatment After Trastuzumab”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Large-scale testing (Phase 3)Study completedNCT00878709
What this trial is testing

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Who this might be right for
Breast Cancer
Puma Biotechnology, Inc. 2,840
Testing effectiveness (Phase 2)UnknownNCT04302441
What this trial is testing

Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
Fudan University 550
Large-scale testing (Phase 3)Study completedNCT01275677
What this trial is testing

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Who this might be right for
HER2/Neu PositiveProgesterone Receptor PositiveRecurrent Breast Carcinoma+6 more
National Cancer Institute (NCI) 3,270
Large-scale testing (Phase 3)Looking for participantsNCT06830889
What this trial is testing

BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

Who this might be right for
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 1,450
Testing effectiveness (Phase 2)UnknownNCT05880927
What this trial is testing

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Taizhou Hospital 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT05480384
What this trial is testing

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Who this might be right for
Esophageal AdenocarcinomaEsophageal CancerHER-2 Protein Overexpression+1 more
Brown University 1
Large-scale testing (Phase 3)Looking for participantsNCT04254263
What this trial is testing

Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

Who this might be right for
Locally Advanced Breast Cancer
RenJi Hospital 316
Testing effectiveness (Phase 2)UnknownNCT01321775
What this trial is testing

Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer

Who this might be right for
Breast Cancer
Hospital Universitario Madrid Sanchinarro 44
Testing effectiveness (Phase 2)Temporarily pausedNCT05062889
What this trial is testing

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Who this might be right for
Stage II Colon CancerStage III Colon CancerHER2-positive Colon Cancer+1 more
Gruppo Oncologico del Nord-Ovest 477
Testing effectiveness (Phase 2)WithdrawnNCT00964704
What this trial is testing

Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche
Testing effectiveness (Phase 2)Study completedNCT02654119
What this trial is testing

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Who this might be right for
HER2 Positive Breast CarcinomaStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7+4 more
University of Nebraska 20
Post-approval studies (Phase 4)Study completedNCT01301729
What this trial is testing

Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Who this might be right for
Breast Cancer
Hoffmann-La Roche 32
Testing effectiveness (Phase 2)Looking for participantsNCT04993014
What this trial is testing

Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer

Who this might be right for
Breast NeoplasmsHER2-positive Breast CancerCirculating Tumor Cell
AC Camargo Cancer Center 80
Large-scale testing (Phase 3)Study completedNCT01772472
What this trial is testing

Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 1,486
Large-scale testing (Phase 3)Study completedNCT02586025
What this trial is testing

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

Who this might be right for
Breast Cancer
Hoffmann-La Roche 329
Large-scale testing (Phase 3)Study completedNCT01966471
What this trial is testing

Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 1,846
Large-scale testing (Phase 3)Looking for participantsNCT05232916
What this trial is testing

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Who this might be right for
Breast Cancer
Greenwich LifeSciences, Inc. 2,250
Large-scale testing (Phase 3)Looking for participantsNCT06876714
What this trial is testing

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Early Stage HER2+ Breast Cancer
Alliance for Clinical Trials in Oncology 1,524
Large-scale testing (Phase 3)Active Not RecruitingNCT04873362
What this trial is testing

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 1,188
Testing effectiveness (Phase 2)UnknownNCT06470347
What this trial is testing

A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy

Who this might be right for
HER-2 Positive Advanced Breast Cancer
Zunyi Medical College 67
Next Page